This resolution designates the majority party's membership on specified Senate committees for the 117th Congress.
This resolution establishes certain procedures for the Senate during the 117th Congress. Specifically, the resolution requires that the committees of the Senate, including joint committees and special committees, be equally composed of members of both parties. The budgets and office space for these committees must also be equal. These ratios shall remain in effect for the duration of the 117th Congress unless a party attains a majority of the whole number of Senators, at which time the ratios must be adjusted to reflect the ratio of the parties in the Senate. Further, the resolution establishes procedures for discharging committees and subcommittees from further consideration of items that have not been reported due to a tie vote, and it prohibits a cloture motion from being filed on an amendable item of business during its first 12 hours of debate.
This resolution designates the minority party's membership on specified Senate committees for the 117th Congress.
This resolution urges the President not to return the United States to the Joint Comprehensive Plan of Action—commonly known as the Iran nuclear deal—unless the agreement is revised and Iran meets specified conditions. Further, the resolution recommends that U.S. sanctions against Iran remain in place until Iran has complied with all elements of a revised agreement.
This resolution expresses the sense of the Senate that the activities of Yevgeniy Prigozhin, his affiliated entities, and the Wagner Group pose a threat to U.S. national security. The resolution calls on the President to work with Congress to develop a strategy to counter these threats. (Prigozhin is a Russian businessman accused of interference in the 2016 U.S. presidential election and the 2018 U.S. midterm elections, and the Wagner Group is a private, Russian paramilitary organization.)
This resolution elects designated Members to specified standing committees of the House of Representatives.
This resolution identifies women's cardiovascular health as an important health care issue and supports gender-specific cardiovascular health research, prevention, and treatment.
This resolution recognizes the contributions of frontline workers and other essential personnel and reaffirms the responsibility of Congress to meet the needs of those workers and the elderly during the COVID-19 (i.e., coronavirus disease 2019) pandemic.
Emergency Care for Veterans During COVID Act This bill requires the Department of Veterans Affairs (VA) to furnish veterans who are enrolled in the VA health care system with emergency treatment at non-VA facilities during the COVID-19 (i.e., coronavirus disease 2019) public health emergency. The VA may not require such veterans to seek authorization for such emergency treatment during this time. The bill also sets forth the payment rates and procedures for such emergency treatment.
Cost Recovery and Expensing Acceleration to Transform the Economy and Jumpstart Opportunities for Businesses and Startups Act or the CREATE JOBS Act This bill allows permanent expensing of qualified property (i.e., property with a recovery period of 20 years or less and that is computer software, water utility property, or film, television, or live theatrical production property). It also modifies depreciation provisions for residential rental property and nonresidential real property. The bill repeals provisions for the amortization of research and experimental expenditures, thus providing for direct expensing of such expenditures.
Federal Actors Lying Should be Eliminated Act or the FALSE Act This bill requires the removal of federal employees who knowingly and willfully make false statements to the government, misappropriate funds, or enter inaccurate information into the government's public spending website (USAspending.gov).
Pandemic Emergency Manufacturing Act of 2021 This bill establishes within the Department of Health and Human Services (HHS) an Emergency Office of Manufacturing for Public Health to manufacture and distribute medical products to address COVID-19 (i.e., coronavirus disease 2019) or medical products that are on shortage or vulnerable to shortage. The office must (1) obtain the rights to manufacture the applicable medicines, ingredients, diagnostic tests, medical devices, personal protective equipment, and supplies; (2) manufacture or contract to manufacture such items; and (3) construct, or enter into construction contracts for, facilities to manufacture certain medicines, such as vaccines. HHS may issue involuntary licenses allowing the office to make, use, sell, import, or export an invention related to an applicable drug, biological product, or device and to use clinical trial data and confidential information. Such a license must provide the rights holder with reasonable compensation. The office must (1) provide such COVID-19 products at no cost to federal, state, local, and other health programs and certain domestic health care providers and suppliers; (2) offer COVID-19 products at cost to other commercial and international entities; and (3) offer other medical products to entities at a fair price, based on cost and other considerations. The office shall prioritize the manufacture of certain COVID-19 products and meet manufacturing timelines specified in the bill.
